How Long Should You Use Mounjaro — and What Happens When You Stop?

Why the question of 'how long' doesn't have a fixed answer

If you're partway through treatment and wondering how much longer this continues, you're not alone, it's the question most people arrive at around month three or four. And it's a fair one, because Mounjaro isn't sold like a course of antibiotics with a clear end point.

The licensed indication covers adults with a BMI of 30 or above, or 27 and above with a weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes. The SmPC sets out a titration schedule from a 2.5 mg starting dose through to a maximum of 15 mg, but it does not cap treatment at a specific number of months. What it does say is that continuation should be reviewed if meaningful progress isn't happening. The full picture of how Mounjaro works helps explain why the pace of progress varies so much between individuals.

NICE's appraisal of tirzepatide (TA1026) adds a useful clinical marker: if someone hasn't achieved at least 5% body-weight reduction after six months at the highest dose they can tolerate, continuing treatment should be reconsidered. That's a decision threshold, not an ejection seat, it prompts a conversation, not an automatic stop. Outside that scenario, there is no ceiling written into the guidance.

What the trial evidence actually tells us about duration

The SURMOUNT-1 trial, published in the New England Journal of Medicine, ran for 72 weeks, that's roughly 17 months. Participants on the 15 mg dose achieved an average body-weight reduction of around 20–21%. What the headline figure doesn't show is the shape of the curve: most of the loss happened in the first year, with the final months consolidating and stabilising rather than accelerating.

That shape matters when you're deciding how long to continue. Weight loss on Mounjaro tends to plateau over time as the body settles at a new point. Reaching that plateau isn't a sign the medicine has stopped working, it may simply mean you've arrived somewhere sustainable. How quickly Mounjaro produces results is a related question worth reading alongside this one, because understanding the early timeline changes how you interpret the later one.

There's also the food-noise effect to consider. Many people find appetite suppression is one of the first things they notice, and how soon that quiets down varies considerably from person to person.

Stopping Mounjaro: what happens, and how to do it thoughtfully

Weight regain after stopping GLP-1 medicines is well-documented. When tirzepatide is discontinued, the appetite signals it was moderating return. For most people that means hunger increases and the spontaneous portion control that felt effortless during treatment becomes effortful again. That's not a personal failing, it reflects how the medicine was working in the first place.

What makes a real difference is how the stop is handled. An abrupt end with no plan tends to produce faster regain than a gradual reduction paired with consolidated lifestyle changes, regular meals, adequate protein, maintained activity. Your prescriber can advise on the right approach for your situation; it's not something to figure out by working backwards from the instructions on the pen.

If you're thinking about the cost side of continuing long-term, what Mounjaro costs privately in the UK is worth reading; understanding the market context helps you weigh up the commitment realistically. And if you've had a break and are considering restarting, how long to stay on Mounjaro covers that restarting process in more detail.

How a prescriber actually makes this call with you

The duration question gets resolved through ongoing clinical review, not a one-time decision. A GPhC-registered prescriber at a regulated service will look at how much weight you've lost and over what period, whether your weight-related conditions have improved, whether you're tolerating the current dose, and what your goals are for stopping or continuing.

That's why how long tirzepatide treatment typically runs can look so different between two people with similar starting points. One person with well-controlled hypertension and 18% weight loss at month twelve may be ready to plan a managed stop. Another with ongoing metabolic risk factors may have strong clinical reasons to continue.

At nume, a real prescriber reviews your case at every repeat order (not software, not a tick-box form) and the clinical team approaches duration as a live question rather than a default setting. The NHS England guidance on weight management injections also outlines what responsible ongoing monitoring should look like, which is useful context whether you're on a private or NHS pathway.

If you're ready to have that conversation, you can start your free consultation with our prescribers today.